Precision Medicine Market Report 2025-2035

The Precision Medicine Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

The Increasing Adoption of Targeted Therapies is Driving Market Growth

The growing focus on treatments customised to each patient's unique characteristics is driving substantial growth in the precision medicine market, supported by the demand for more effective, personalised therapies with fewer adverse effects. With increasing cases of cancer, rare genetic disorders, and chronic diseases, biomarker-based therapies and companion diagnostics are proving highly impactful. This has led to greater investment from pharma companies and research institutions in developing treatments tailored to individual genetic profiles.

For instance, on December 20, 2024, Pfizer's BRAFTOVI, a combination treatment targeting metastatic colorectal cancer with the BRAF V600E mutation, received approval from the U.S. Food and Drug Administration (FDA). Similarly, on November 27, 2024, the European Commission granted approval for Novartis' Kisqali to treat a broader population of patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer who face a high risk of recurrence. These approvals highlight the rising focus on genetically guided treatments, set to transform the precision medicine landscape by enhancing survival rates and patient outcomes. With ongoing advances in genomic sequencing, AI-driven analytics, and liquid biopsy technologies, the demand for targeted therapies is expected to grow rapidly, solidifying precision medicine as a key pillar of future healthcare.

Lack of Interoperability Across Healthcare Data Systems Is Likely to Hinder Market Growth

One of the key barriers to realizing the full potential of precision medicine is the lack of interoperability across healthcare data systems. Precision medicine depends on the seamless integration of genomic data, electronic health records (EHRs), real-world evidence, and biomarker insights but fragmented data sources hinder this process. Without standardized frameworks for data sharing, clinicians, researchers, and pharma companies face difficulties in accessing and utilizing patient-specific information effectively.

For instance, genomic data from sequencing platforms often don't align with hospital EHR systems, limiting physicians' ability to make informed treatment decisions. Patients receiving care from multiple providers may also experience fragmented records, reducing the effectiveness of personalized therapies. This data disconnect extends to pharmaceutical R&D, where incomplete datasets slow down biomarker discovery and clinical trials. Overcoming these challenges calls for standardized data exchange protocols, AI-powered integration tools, and stronger collaboration among healthcare providers, tech developers, and regulators to drive progress in precision medicine.

What would be the Impact of the U.S. Trade Tariffs on the Global Precision Medicine Market?

The impact of the U.S. trade tariffs extends beyond production to the accessibility and affordability of precision medicine solutions for patients. As manufacturers pass increased costs down the supply chain, hospitals and clinics may be forced to charge more for advanced genomic tests, targeted therapies, and personalised diagnostics services that are already relatively expensive. This price inflation risks widening the healthcare gap, making precision medicine even less accessible in underfunded or rural healthcare systems, both in the U.S. and abroad. In countries that rely heavily on the U.S.-based technologies or partnerships, these disruptions could delay the adoption of new medical innovations, particularly those tailored to specific genetic or regional population needs.

The precision medicine market thrives on global collaboration among researchers, data scientists, and clinicians across borders, who often share genomic datasets, clinical trial resources, and AI-based diagnostic tools. Trade tensions and tariffs can create a ripple effect, weakening international research alliances and data-sharing efforts due to increased compliance barriers, licensing issues, or protectionist policies.

What Questions Should You Ask before Buying a Market Research Report?

• How is the precision medicine market evolving?
• What is driving and restraining the precision medicine market?
• How will each precision medicine submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
• How will the market shares for each precision medicine submarket develop from 2025 to 2035?
• What will be the main driver for the overall market from 2025 to 2035?
• Will leading precision medicine markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
• Who are the leading players and what are their prospects over the forecast period?
• What are the precision medicine projects for these leading companies?
• How will the industry evolve during the period between 2025 and 2035? What are the implications of precision medicine projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the precision medicine market?
• Where is the precision medicine market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the precision medicine market today, and over the next 10 years:

• Our 463-page report provides 187 tables, 293 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2035 and other analysis reveal commercial prospects

• In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
• You will find original analysis, with business outlooks and developments.
• Discover qualitative analysis (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising precision medicine prices and recent developments.

Segments Covered in the Report

Product

• Therapeutics
  - Monoclonal Antibodies
  
  - Inhibitor Drugs
  
  - Cell & Gene Therapies
  
  - RNA-Based Therapies
  
  - Others


• Diagnostics
  - Genetic Tests
  
  - Biomarker-based Tests
  
  - Other Diagnostic Tests

Application

• Oncology
• Immunology
• CNS
• Respiratory
• Others

Technology

• Gene Sequencing
• Drug Discovery
• Big Data Analytics
• Companion Diagnostics
• Bioinformatics
• Other Technologies

End-users

• Hospitals
• Diagnostic Centers
• Research & Academic Institutes
• Other End-users

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Denmark
• Rest of Europe

Asia Pacific

• Japan
• China
• India
• Australia
• South Korea
• Singapore
• Thailand
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Precision Medicine Market, 2025 to 2035, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

• 23andMe, Inc.
• Abbott
• Abnova Corporation
• Adaptive Biotechnologies
• Agilent Technologies Inc.
• AstraZeneca
• Bayer AG
• Biogen
• bioMerieux SA
• Bristol-Myers Squibb Company
• Bruker Corporation
• Danaher
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GE HealthCare
• GRAIL Inc.
• GSK plc
• Illumina, Inc.
• Johnson & Johnson
• Laboratory Corporation of America Holdings
• Myriad Genetics Inc
• Novartis AG
• Pfizer Inc.
• Qiagen
• Quest Diagnostics Incorporated
• Regeneron Pharmaceuticals
• Tempus
• Teva Pharmaceutical Industries Ltd.

Overall world revenue for Precision Medicine Market, 2025 to 2035 in terms of value the market will surpass US$150 billion in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Precision Medicine Market, 2025 to 2035 report help you?

In summary, our 460+ page report provides you with the following knowledge:

• Revenue forecasts to 2035 for Precision Medicine Market, 2025 to 2035, with forecasts for product, application, technology, and end-user, each forecast at a global and regional level – discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2035 for five regional and 25 key national markets – See forecasts for the Precision Medicine Market, 2025 to 2035 in North America, Europe, Asia Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 28 of the major companies involved in the Precision Medicine Market, 2025 to 2035.

Find quantitative and qualitative analysis with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher Show more